The Clock Is Ticking on Two Fronts: A June Hearing for Marijuana, a July Deadline for Hemp

The Clock Is Ticking on Two Fronts: A June Hearing for Marijuana, a July Deadline for Hemp

Cannabis policy in America has rarely felt as bifurcated as it does this week. On one track, marijuana is moving — haltingly, contentiously — toward looser federal control. On another, the hemp-derived products that have flooded gas stations and smoke shops are being squeezed toward extinction. Two countdowns now define the landscape: a late-June federal hearing that could decide marijuana's broader status, and a July 1 deadline in Tennessee that previews the reckoning facing intoxicating hemp nationwide. For consumers and operators alike, the question is no longer whether the rules are changing, but which way they break.

Start with the marijuana side, where the foundational shift is already in place. Following President Trump's December 2025 executive order, the Justice Department and DEA placed FDA-approved marijuana products and state-licensed medical marijuana products into Schedule III of the Controlled Substances Act. That move, finalized in the spring, reclassified medical cannabis from the most restrictive federal category — Schedule I, alongside heroin — to a tier reserved for drugs with accepted medical use. The next chapter begins this month. The DEA has scheduled an administrative hearing to commence June 29 at 9 a.m. ET in Arlington, Virginia, concluding no later than July 15, to evaluate whether marijuana as a whole — not just FDA-approved and state-licensed medical products — should be reclassified to Schedule III.

For consumers, the practical near-term impact at the dispensary counter is limited; state programs continue to operate under state law regardless of the federal tier. The deeper significance is financial and scientific. A full Schedule III reclassification would relieve plant-touching businesses of Section 280E, the tax provision that bars them from deducting ordinary expenses and has functioned as an effective penalty on the entire legal industry. It would also ease the path for clinical research that has long been throttled by Schedule I red tape.

But the legal ground beneath all of this is contested, and that was the week's running subplot. Fresh analysis argued that the post-Chevron regulatory landscape may expose the DEA's scheduling procedures to constitutional challenge, and observers are watching whether the acting attorney general's use of treaty-implementation authority as the legal basis for the immediate rescheduling order can survive judicial scrutiny. Opposition groups that stalled the earlier Biden-era process have signaled they will challenge the rescheduling order and participate aggressively in the June proceedings. If the process holds, a final rule on broader rescheduling could arrive as early as late 2026; if litigation or congressional action intervenes, it could slip into 2027 or beyond. For operators, the takeaway is to plan for relief without banking on its timing.

While marijuana edges toward liberalization, the hemp side is moving the opposite direction — and nowhere more starkly than Tennessee. Beginning July 1, the sale of THCA and other intoxicating hemp-derived products becomes illegal in the state, as the Tennessee Alcoholic Beverage Commission assumes full regulatory control of hemp. The numbers explain why the industry is alarmed: roughly 75% of Tennessee hemp sales derive from THCA, and state officials have already slashed their hemp wholesale tax projections from more than $55 million to under $10 million annually. The underlying legislation, signed May 21, not only bans THCA and synthetic cannabinoids but also prohibits direct-to-consumer sales and strips the state's Department of Agriculture of hemp oversight, handing that authority to the ABC. Businesses licensed as of December 31, 2025 were allowed to keep selling under the old framework through June 30 under a deal that resolved threatened litigation — but that grace period now expires.

What's happening in Tennessee is a preview of a federal squeeze already written into law. The 2026 funding bill signed November 12, 2025 effectively bans intoxicating hemp products, limiting finished hemp-derived products to no more than 0.4 milligrams of total THC per container. Enforcement is deferred 365 days, taking effect in November 2026, at which point non-compliant products become marijuana under federal law. The U.S. Hemp Roundtable estimates the redefinition would eliminate roughly 95% of existing hemp-derived cannabinoid products, costing more than 300,000 jobs and $1.5 billion in state tax revenue. The 2026 Farm Bill, which the House passed 224-200 on April 30 with the intoxicating-hemp ban intact, now sits with the Senate.

For operators, the divergence demands a strategic pivot: the regulated marijuana channel is gaining legitimacy while the hemp gray market faces closure. Not every state is tightening — Iowa's governor signed legislation this month to double the number of medical marijuana dispensaries, a reminder that expansion and contraction are happening simultaneously across the country. For consumers, the message is more immediate: the THCA gummy on the gas-station shelf may not be there much longer, while the licensed dispensary down the road is, if anything, becoming a more permanent fixture. The coming weeks will tell which countdown reshapes the market first.